60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) released its earnings results on Monday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14), FiscalAI reports. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.27 million.
60 Degrees Pharmaceuticals Stock Performance
NASDAQ:SXTP traded down $0.03 during mid-day trading on Monday, hitting $0.49. 51,632 shares of the stock were exchanged, compared to its average volume of 1,436,915. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $8.62. The stock has a market capitalization of $1.71 million, a price-to-earnings ratio of -0.10 and a beta of 2.47. The firm’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.65.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $13.85.
Read Our Latest Stock Analysis on 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other parasitic infections. Its portfolio includes tafenoquine, an antimalarial medicine marketed in the United States as ARAKODA for the prevention of malaria in adults. The company is also studying tafenoquine for potential use against babesiosis, a tick-borne parasitic disease. These development programs are investigational; tafenoquine’s approval for malaria prevention does not extend to babesiosis.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
